Chosen to Head Decentralized Trials & Research
Alliance Regulatory Gap Initiative

Clinical Ink, a global clinical trial technology company, today announced that CBO Jonathan Andrus has been selected to co-lead the Decentralized Trials & Research Alliance’s (DTRA) Initiative 4B: Collaborate on Regulatory Gaps. Building on his extensive relationships with the EMA, FDA, MHRA, and other agencies in driving industry collaboration, Andrus will lead this component of a Priority Initiative — one of four — that the DTRA has established to guide industry leadership and growth:

• Definitions: come up with common terminology/descriptions of various aspects of decentralized trials
• Best Practices: focus on implementation
• Education: patient, site, and sponsor content to help make the benefits clear
• Removing Barriers: identify and remove barriers to decentralized research implementation, establishing road maps to their resolution

Along with co-leader Chantal Le Floch, Andrus will draw on his extensive decentralized trial (DCT) experience as he facilitates and co-creates workshops while organizing the initiative team and executing all related activities. Selected from 220 individual nominees, Andrus’ selection affirms Clinical Ink’s leadership position as the premier provider of DCT solutions for clinical trials. 

“I’m humbled to have been chosen to further such an important initiative,” said Andrus. “We have an opportunity to craft a regulatory blueprint and establish a DCT regulatory framework that will benefit patients for years to come. I am honored to contribute to the evolutionary framework of both DCT technology and the clinical trials industry as a whole.” 

The DTRA was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused DCTs and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. 

About Clinical InkClinical Ink, a global clinical technology company, offers data certainty from source to submission via our Lunexis eSource clinical technology and configurable direct data capture, eCOA, ePRO+, and eConsent modules. This suite of solutions for capturing and integrating electronic data from sites, clinicians, patients, and caregivers at its source naturally enhances clinical trial workflows. For virtual, traditional, or hybrid trials, Lunexis technology reduces manual labor and associated delays, and provides anytime, anywhere data access, saving resources as your trials progress. For more information, visit clinicalink.com.